New England Research & Management Inc. Buys Shares of 5,080 IQVIA Holdings Inc. $IQV

New England Research & Management Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 5,080 shares of the medical research company’s stock, valued at approximately $1,145,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Everpar Advisors LLC boosted its position in shares of IQVIA by 50.0% in the 4th quarter. Everpar Advisors LLC now owns 2,094 shares of the medical research company’s stock worth $472,000 after purchasing an additional 698 shares in the last quarter. Park Avenue Securities LLC increased its position in IQVIA by 4.1% during the 4th quarter. Park Avenue Securities LLC now owns 6,735 shares of the medical research company’s stock valued at $1,518,000 after buying an additional 266 shares in the last quarter. Legacy Wealth Management LLC MS raised its stake in IQVIA by 8.1% in the fourth quarter. Legacy Wealth Management LLC MS now owns 20,640 shares of the medical research company’s stock valued at $4,652,000 after buying an additional 1,545 shares during the last quarter. GAMMA Investing LLC boosted its holdings in IQVIA by 10.3% in the fourth quarter. GAMMA Investing LLC now owns 3,765 shares of the medical research company’s stock worth $849,000 after acquiring an additional 351 shares in the last quarter. Finally, Allworth Financial LP grew its stake in shares of IQVIA by 68.8% during the third quarter. Allworth Financial LP now owns 1,637 shares of the medical research company’s stock worth $311,000 after acquiring an additional 667 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQV opened at $165.91 on Friday. The firm has a fifty day moving average price of $194.13 and a 200 day moving average price of $206.03. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The stock has a market cap of $28.16 billion, a P/E ratio of 21.11, a P/E/G ratio of 1.60 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Stifel Nicolaus cut their price objective on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Jefferies Financial Group dropped their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. UBS Group cut their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Mizuho set a $215.00 price target on shares of IQVIA in a report on Monday, February 23rd. Finally, TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Buy” and a consensus target price of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.